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Identity 
Other names: DNMT3A2, M.HsaIIIA 
HGNC (Hugo): DNMT3A 
Location: 2p23.3 
Local order: The human DNMT3A is telomeric to 
DTNB (dystrobrevin, beta) and centromeric to 
POMC (proopiomelanocortin). 
Note 
DNA methylation occurs mainly in the cytosine 
residues at the C5 positions of CpG dinucleotides and 
is important in regulating gene expression, parental 
imprinting, and maintenance of the genome integrity in 
mammalian cells (Chen and Li, 2006). Aberrant DNA 
methylation has been reported to play a vital role in the 
pathogenesis of acute myeloid leukemia (AML) 
(Rosenbauer and Tenen, 2007).  
In addition, differences in global DNA methylation 
signatures have been reported to be associated with 
differences in treatment outcome for patients with 
AML (Figueroa et al., 2010a; Figueroa et al., 2010b; 
Melnick, 2010). 
Genome-wide DNA methylation patterns are 
established and maintained by the coordination of 
DNMT1 and DNMT3 families of DNA 
methyltransferases. DNMT1 carries out most of the 
maintenance methylation following DNA replication, 
whereas DNMT3A and DNMT3B are responsible for 
de novo methylation during mammalian development 
(Brenner and Fuks, 2006; Hermann et al., 2004). 
Recent studies showed that Dnmt1 is required for 
hematopoietic stem cell proliferation and 
myeloid/lymphoid differentiation (Trowbridge et al., 
2009).  
In contrast, conditional deletion of Dnmt3a and 
Dnmt3b in mouse hematopoietic stem cells impaired 
self- renewal but not lineage determination, indicating 
the role of de novo DNA methyltransferase for self-
renewal in hematopoietic stem cells (Tadokoro et al., 
2007).  
The third member of the DNMT3 family is DNMT3L 
which does not have enzymatic activity due to the lack 
of some critical catalytic motifs (Brenner and Fuks, 
2006).  
It regulates the catalytic activity of DNMT3A and 3B 
(Hata et al., 2002; Suetake et al., 2004). 
DNA/RNA 
Description 
The DNMT3A gene structure is composed of 23 exons 
(Xie et al., 1999).  
A short isoform, named DNMT3A2, is produced from 
a downstream intronic promoter (Chen et al., 2002). 
Transcription 
Transcription of DNMT3A is initiated from the 
downstream intronic promoter and leads to expression 
of DNMT3A2, an isoform lacking the N-terminal 
region, in embryonic stem cells (ESCs). Expression of 
this shorter isoform gradually decreases upon ESC 
differentiation and switches to the full length 
DNMT3A which remains expressed at low level in 
most somatic tissues (Chedin, 2011; Chen et al., 2002). 
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AA: 912. EC number: 2.1.1.37. Estimated molecular 
weight: 101858 Dt. 
DNMT3A2 
AA: 689. Estimated molecular weight: 77817 Dt. 
DNMT3A contains 3 main structure domains: a 
proline-tryptophan-tryptophan-proline (PWWP) 
domain, an ATRX, DNMT3, and DNMT3L-type zinc 
finger (ADD) domain, and the methyltransferase 
(Mtase) domain. The PWWP domain is responsible for 
targeting the enzyme to nucleic acid (Chen et al., 
2004). In addition, the PWWP domain is also essential 
for targeting this enzyme to pericentric heterochromatin 
(Chen et al., 2004; Ge et al., 2004). The ADD domain 
mediates protein-protein interactions with transcription  
factors Myc, RP58, the heterochromatin protein HP1, 
histone deacetylases, and the histone methyltransferase 
Suv39h1 (Chen and Li, 2006). The Mtase domain 
contains six highly conserved cytosine C5-DNA 
methyltransferase motifs (Jurkowska et al., 2011). 
Expression 
In mouse, Dnmt3a was detected in all tissues except for 
small intestines, whereas Dnmt3a2 expression was 
more restricted in testis, spleen and thymus (Chen et 
al., 2002).  
In addition to normal tissues, overexpression of 
DNMT3A has been reported in various human cancers, 
such as prostate, pancreatic, gastric, liver cancers 
(Gravina et al., 2013; Oh et al., 2007; Yang et al., 2011; 
Zhang et al., 2012). Additionally, DNMT3A were 
detected substantially overexpressed in certain types of 
leukemia (Mizuno et al., 2001). 
 
Structure of DNA methyltransferases. NLS, nuclear localization signal; CXXC, a cysteine rich region; BAH, a bromo-adjacent 
homology domain; PWWP, a proline-tryptophan-tryptophan-proline domain; ADD, an ATRX-DNMT3-DNMT3L-type zinc finger domain; 
Mtase, a methyltransferase domain. 
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Localisation 
Dnmt3a localizes in the nuclei and is concentrated in 
nuclear foci.  
In contrast, Dnmt3a2 showed a diffused pattern 
excluding nucleoli and heterochromatin.  
In general, Dnmt3a is thought to associate with 
heterochmatin, whereas Dnmt3a2 associates mainly 
with euchromatin (Chen et al., 2002). 
Function 
Similarly to Dnmt1, the Dnmt3a enzyme also uses S-
adenosyl methionine (SAM) as the methyl group donor 
being transferred to the carbon 5 position of the 
cytosine ring in CpG dinucleotide in DNA.  
It is essential for the establishment of DNA methylation 
patterns during development (Jurkowska et al., 2011). 
In addition to the enzymatic function, Dnmt3a was also 
shown to suppress transcription, independent of its 
catalytic activity, that was mediated through the 
interaction with the histone deacetylase and other co-
repressors, such as Mbd3 and Brg1 (Datta et al., 2005; 
Fuks et al., 2001).  
Sumoylation of DNMT3A has been reported in the N-
terminal domain of the enzyme, which disrupts its 
interaction with histone deacetylases (HDACs) and 
thereby impairs the repressive capability of this protein 
(Ling et al., 2004). 
Homology 
Dnmt3 family proteins share some structural similarity 
with Dnmt1 at c-terminal Mtase domain. In addition, 
the DNMT3A and DNMT3B proteins also contain a 
conserved cystein-rich ATRX, DNMT3, and 
DNMT3L-type zinc finger (ADD) domain and the 
proline-tryptophan-tryptophan-proline (PWWP) 
domain.  
The N-terminal domains of Dnmt3a and Dnmt3b do not 
share any sequence homology (Chedin, 2011). 
Mutations 
Somatic 
Recurrent DNMT3A gene mutations were recently 
reported in acute myeloid leukemia (AML), 
myelodysplastic syndrome (MDS), myeloproliferative 
neoplasms (MPN), T-cell lymphoma, and T-cell acute 
lymphoblastic leukemia (ALL) (Couronne et al., 2012; 
Grossmann et al., 2013; Hou et al., 2012; Ley et al., 
2010; Stegelmann et al., 2011; Walter et al., 2011). The 
most frequently mutated site is the Arg 882 (R882) 
residue located in the catalytic domain. These R882 
mutants were reported to reduce DNA methylation 







Acute myeloid leukemia (AML) 
Note 
DNMT3A mutations frequently detected in 7-29% of 
AML patients. This mutation was associated with 
normal karyotype, older age, French-American-British 
(FAB) M4/M5 subtypes, and poor prognosis.  
Multivariate analysis demonstrated that the DNMT3A 
mutation was an independent poor prognostic factor for 
over-all survival and relapse-free survival (Hou et al., 
2012; Ley et al., 2010; Thol et al., 2011a; Yan et al., 
2011).  
This mutation was also reported in 35.1% of secondary 
AML and 16.4% of therapy-related AML in a study of 
a cohort of 98 patients and found that this mutation was 
associated with normal karyotype and IDH1/IDH2 
mutations, but that it does not affect survival (Shih et 
al., 2013).  
Recent reports further demonstrated that the frequency 
of DNMT3A mutations is rare in childhood AML and 
MDS, suggesting that the frequency of DNMT3A gene 
mutation depends on age (Ho et al., 2011; Thol et al., 
2011b).  
In addition, it was also reported that AML patients 
whose leukemic blasts have low DNMT3A activity, 
either due to loss-of-functions or low gene expression, 
may benefit from treatment with hypomethylating 
agents (Metzeler et al., 2012). 
Myelodysplastic syndrome (MDS) 
Note 
Mutations of the DNMT3A gene were detected in 6% 
of MDS patients and amino acid R882 was the most 
common mutation site.  
Patients with DNMT3A mutations had worse overall 
survival compared with patients without these 
mutations and more rapid progression to AML (Walter 
et al., 2011). 
Myeloproliferative neoplasms (MPN) 
Note 
In a study of a cohort of 155 patients with MPN, an 
overall frequency of 10% mutations were most 
frequently detected in secondary AML (sAML: 17%) 
and myelofibrosis (MF: 15%), followed by 
polycythemia vera (PV: 7%) and essential 
thrombocythemia (ET: 3%).  
These alterations occurred concurrently with JAK2, 
IDH1/2 and ASXL1 mutations.  
In addition, these mutations are associated with more 
advanced stages of MPNs and with an overall poor 
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T-cell lymphoma 
Note 
DNMT3A mutations were reported in eleven of 98 
patients with T-cell lymphoma and were associated 
with TET2 mutations (Couronne et al., 2012). 
T-cell acute lymphoblastic leukemia (T-
ALL) 
Note 
DNMT3A mutations were detected in 16 of 90 patients 
(17.8%) with T-ALL.  
These alterations were associated with normal 
karyotype, lower hemoglobin levels and mutually 
exclusive in cases with CDKN2A/CDKN2B deletions. 
Further, these mutations had a strong association with 
shorter overall survival (Grossmann et al., 2013). 
Lung cancer 
Note 
Deletion of Dnmt3a significantly promotes tumor 
growth and progression in lung cancer mouse model, 
suggesting that this gene may act like a tumor-
suppressor gene and may be a crucial factor of lung 
cancer malignancy (Gao et al., 2011). 
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